NCT05569681
Two Different Regimens of Bemiparin as a Thromboprophylaxis in Morbidly Obese Surgical Patients
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 9 versions: 8 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Minor Trial completed Show 4 more changesShow less
- Final enrollment: 1248 participants (planned 2400)
- Primary completion date changed from estimate of Sep 25, 2026 to Oct 20, 2026
- Study completion date changed from estimate of Oct 2, 2026 to Oct 23, 2026
- Site details revised
- Notable Eligibility criteria shortened, about 6 words
- Primary completion date: Sep 2, 2026 to Sep 25, 2026
- Notable Primary completion date: Feb 2, 2026 to Sep 2, 2026
- Study completion date: Apr 2, 2026 to Oct 2, 2026
- Minor Study description expanded, about 91 wordsv6
- Notable Eligibility criteria shortened, about 2 wordsv5
Show 2 earlier versionsHide 2 earlier versions
Notable Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
- Primary completion date: Feb 2, 2025 to Feb 2, 2026
- Study completion date: Apr 2, 2025 to Apr 2, 2026
- Start date changed from estimate of Dec 2, 2022 to Jan 7, 2023
- Site details revised
- Notable Primary endpoint revisedv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (1)
Arms and interventions
Bemiparin sodium 3,500 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group and for 30 days in very high risk-group patients according to Caprinin risk classification for venous thromboembolism. Other Name: Hibor; Laboratories Rovi Pharmaceuticals
Bemiparin sodium 5000 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group patients and 30 days in very high-risk group surgical patients according to Caprinin risk classification for venous thromboembolism. Other Name: Hibor; Laboratories Rovi Pharmaceuticals
Drugs: Bemiparin 3500, Bemiparin 5000 IU
Sites
1 site in 1 country
- Hawler Medical universityErbil, Kurdistan Region, Iraq